Kalaris Therapeutics (KLRS) Stock Price, News & Analysis

Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $3.88 to $4.15
• 50-Day Range: $3.34 to $4.83
• 52-Week Range: $2.31 to $11.88
• Volume: 28,091 shs
• Average Volume: 664,319 shs
• Market Capitalization: $97.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.75
• Consensus Rating: Moderate Buy

Kalaris Therapeutics Stock Analysis - MarketRank™

Kalaris Therapeutics scored higher than 79% of companies evaluated by MarketBeat, and ranked 54th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kalaris Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Kalaris Therapeutics has a consensus price target of $18.75, representing about 359.6% upside from its current price of $4.08.

Amount of Analyst Coverage

Kalaris Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Kalaris Therapeutics are expected to remain at ($1.99) per share in the coming year.

Price to Book Value per Share Ratio

Kalaris Therapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.42% of the float of Kalaris Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kalaris Therapeutics has a short interest ratio ("days to cover") of 0.39, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kalaris Therapeutics has recently decreased by 20.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kalaris Therapeutics does not currently pay a dividend.

Dividend Growth

Kalaris Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.84

News Sentiment

Kalaris Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Kalaris Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $1,179,969.00 in company stock, which represents 1.2146% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Kalaris Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,179,969.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

68.10% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 8/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KLRS
• CIK: 1754068
• Web: allovir.com
• Phone: (617) 433-2605
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kalaris Therapeutics: $18.75
• High Price Target: $25.00
• Low Price Target: $14.00
• Potential Upside/Downside: +359.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.17%
• Return on Assets: -42.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.19
• Quick Ratio: 12.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.21 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 23,810,000
• Free Float: 7,590,000
• Market Cap: $97.14 million
• Optionable: N/A
• Beta: 0.20